On June 20, 2019 The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) is collaborating with AstraZeneca, a global, science-led biopharmaceutical company, to further quality in cancer care for people with advanced ovarian cancer (Press release, AstraZeneca, JUN 20, 2019, View Source [SID1234537201]). This follows a recently announced and still active request for proposals, also in collaboration with AstraZeneca, on innovative approaches for improving care in unresectable stage III and IV non-small cell lung cancer. Letters of intent are due Monday, July 22, 2019, for this new opportunity, which is available to researchers at any of the 28 NCCN Member Institutions.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Advanced and recurrent ovarian cancer remains a treatment challenge," explained Wui-Jin Koh, MD, Chief Medical Officer, NCCN. "It’s currently the deadliest gynecologic cancer, and requires a coordinated, multi-disciplinary approach. With this project, we’re looking for research that focuses on how to optimize multiple facets of management effectiveness by harnessing innovative technologies or addressing knowledge gaps."
Some areas of particular interest for proposals include:
Adhering to standard of care management
Delivering care through innovative methods (e.g. telemedicine and/or coordination of care between academic centers and community practices)
Improving adoption of appropriate genetic testing
Discovering new strategies for sharing and implementing novel findings expeditiously
Creating shared decision-making models
Improving the use of supportive services
Utilizing technology to enhance quality of life in patients
Proposals that are reproducible, scalable, rapidly implementable, and provide quantifiable outcome measures are preferred. NCCN ORP is also interested in discovering concepts to reduce financial toxicity, manage care across multiple facilities, increase clinical trial enrollment, and enhance shared decision-making and patient information.
The NCCN ORP fosters innovation and knowledge discovery that improve the lives of patients with cancer. Collaboration between NCCN Member Institutions is strongly encouraged in order to cultivate interactive sharing of knowledge and expertise, and to utilize the combined strengths of members. For more information and to read the entire Request for Proposals, visit NCCN.org/ORP.